Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

827

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Non-erosive Gastroesophageal Reflux Disease
Interventions
DRUG

TAK-438

TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.

DRUG

TAK-438

TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.

DRUG

Placebo

TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.

Trial Locations (52)

Unknown

Nagoya

Abiko-shi

Kashiwa-shi

Noda

Yachiyo-shi

Saijo-shi

Fukuoka

Itoshima-shi

Kasuya-gun

Onga-gun

Kouriyama-shi

Gifu

Takayama-shi

Annaka-shi

Hiroshima

Asahikawa-shi

Sapporo

Amagasaki-shi

Kobe

Nishinomiya-shi

Takarazuka-shi

Sagamihara-shi

Yokohama

Kochi

Suzaki-shi

Kumamoto

Kyoto

Sendai

Nagasaki

Ōita

Okayama

Osaka

Takatsuki-shi

Saga

Kumagaya-shi

Saitama-shi

Tokorozawa-shi

Otawara-shi

Bunkyo-ku

Chiyoda-ku

Chuo-ku

Hachioji-shi

Kokubunji-shi

Nakano-ku

Oota-ku

Setagaya-ku

Shibuya-ku

Shinjuku-ku

Shimonoseki-shi

Kofu

Turu-shi

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY